NASDAQ:BPTHBio-Path Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bio-Path Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.74 -0.07 (-1.46 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$4.70Now: $4.74▼$4.8950-Day Range$4.81MA: $5.12▼$5.4952-Week Range$2.92Now: $4.74▼$13.41Volume37,500 shsAverage Volume93,685 shsMarket Capitalization$17.50 millionP/E RatioN/ADividend YieldN/ABeta2.49 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Bio-Path has a potential upside of 279.7% from its current price of $4.74.Amount of Analyst CoverageBio-Path has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesBio-Path has received 261 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBio-Path has received 225 “underperform” votes. (Add your “underperform” vote.)Community SentimentBio-Path has received 53.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote “Outperform” if you believe BPTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.84% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 9.71% of the stock of Bio-Path is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($3.77) to ($2.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Path is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Path is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPTH Previous Symbol CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone832-742-1357Debt Debt-to-Equity Ratio0.02 Current Ratio12.09 Quick Ratio12.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales437.50 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book0.65Profitability EPS (Most Recent Fiscal Year)($3.24) Net Income$-8,600,000.00 Net MarginsN/A Return on Equity-56.95% Return on Assets-52.33%Miscellaneous Employees8 Outstanding Shares3,692,000Market Cap$17.50 million Next Earnings Date8/14/2020 (Confirmed) OptionableNot Optionable $4.74 -0.07 (-1.46 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BPTH News and Ratings via Email Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Bio-Path (NASDAQ:BPTH) Frequently Asked Questions How has Bio-Path's stock price been impacted by Coronavirus (COVID-19)? Bio-Path's stock was trading at $4.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BPTH stock has decreased by 0.2% and is now trading at $4.74. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Bio-Path? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bio-Path. When is Bio-Path's next earnings date? Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Bio-Path. How were Bio-Path's earnings last quarter? Bio-Path Holdings Inc (NASDAQ:BPTH) issued its earnings results on Friday, August, 14th. The company reported ($0.55) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.34. View Bio-Path's earnings history. When did Bio-Path's stock split? How did Bio-Path's stock split work? Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for BPTH? 1 analysts have issued 1 year price objectives for Bio-Path's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Bio-Path's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 279.7% from the stock's current price. View analysts' price targets for Bio-Path. What are Wall Street analysts saying about Bio-Path stock? Here are some recent quotes from research analysts about Bio-Path stock: 1. According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (7/20/2020) 2. HC Wainwright analysts commented, "We believe quarterly operating expenses could approximate $2M in 2H19. The company had $17.1M in cash at the end of June 2019, which should support operations into 2H20. In the wake of this update, we reiterate our Buy rating and $28 price target. Combo trial of prexigebersen + decitabine could report safety data in 2H19. Prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with acute myeloid leukemia (AML), demonstrating 65% objective response with a 29% complete response (CR) rate." (8/16/2019) Has Bio-Path been receiving favorable news coverage? News headlines about BPTH stock have trended very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bio-Path earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Bio-Path. Are investors shorting Bio-Path? Bio-Path saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 15,300 shares, an increase of 62.8% from the June 15th total of 9,400 shares. Based on an average daily volume of 95,400 shares, the days-to-cover ratio is presently 0.2 days. View Bio-Path's Short Interest. Who are some of Bio-Path's key competitors? Some companies that are related to Bio-Path include Enlivex Therapeutics (ENLV), Edesa Biotech (EDSA), Acasti Pharma (ACST), Mereo BioPharma Group (MREO), Proteostasis Therapeutics (PTI), Infinity Pharmaceuticals (INFI), Catalyst Biosciences (CBIO), Stealth BioTherapeutics (MITO), SCYNEXIS (SCYX), Aridis Pharmaceuticals (ARDS), Lantern Pharma (LTRN), CannTrust (CNTTF), Assertio Therapeutics (ASRT), Soligenix (SNGX) and CV Sciences (CVSI). View all competitors. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), NVIDIA (NVDA), Energy Transfer LP Unit (ET), Amarin (AMRN), Canopy Growth (CGC), Micron Technology (MU), Palatin Technologies (PTN), Advanced Micro Devices (AMD) and Ford Motor (F). Who are Bio-Path's key executives? Bio-Path's management team includes the following people: Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 70)Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 63)Mr. Anthony Price MBA, Director of Fin. and AccountingDr. Alan MacKenzie Ph.D., ConsultantDr. Thomas A. Walker Ph.D., Consultant What is Bio-Path's stock symbol? Bio-Path trades on the NASDAQ under the ticker symbol "BPTH." How do I buy shares of Bio-Path? Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Bio-Path's stock price today? One share of BPTH stock can currently be purchased for approximately $4.74. How big of a company is Bio-Path? Bio-Path has a market capitalization of $17.50 million and generates $40,000.00 in revenue each year. The company earns $-8,600,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. Bio-Path employs 8 workers across the globe. What is Bio-Path's official website? The official website for Bio-Path is www.biopathholdings.com. How can I contact Bio-Path? Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
